{"id":"mepolizumab-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Pyrexia"},{"rate":null,"effect":"Back pain"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108429","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-5 is a key cytokine responsible for eosinophil recruitment, activation, and survival. By blocking IL-5, mepolizumab reduces circulating and tissue eosinophil levels, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly effective in eosinophil-driven diseases such as severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).","oneSentence":"Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:52.840Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe eosinophilic asthma"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"},{"name":"Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)"}]},"trialDetails":[{"nctId":"NCT04183192","phase":"PHASE1","title":"Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-02-17","conditions":"Healthy Subjects, Pharmacokinetics, Pharmacodynamics","enrollment":72},{"nctId":"NCT01362244","phase":"PHASE2","title":"Mepolizumab in Nasal Polyposis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-12","conditions":"Nasal Polyps","enrollment":109},{"nctId":"NCT01691521","phase":"PHASE3","title":"Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-08","conditions":"Asthma","enrollment":580},{"nctId":"NCT00358449","phase":"PHASE2","title":"Intravenous Mepolizumab In Children With Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-11","conditions":"Oesophagitis, Eosinophilic","enrollment":84},{"nctId":"NCT01471327","phase":"PHASE1","title":"Japanese Phase 1 Study of Mepolizumab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-08-09","conditions":"Asthma","enrollment":35},{"nctId":"NCT00527566","phase":"PHASE1, PHASE2","title":"Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2007-09","conditions":"Churg Strauss Syndrome","enrollment":10},{"nctId":"NCT00716651","phase":"PHASE2","title":"Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2008-07","conditions":"Churg Strauss Syndrome","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mepolizumab IV","genericName":"Mepolizumab IV","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA), Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}